Abstract:Parkinson's disease (PD) is the second most common cause of neurodegeneration. Over the last two decades, various hypotheses have been proposed to explain the etiology of PD. Among these is the oxidant-antioxidant theory, which asserts that local and systemic oxidative damage triggered by reactive oxygen species and other free radicals may promote dopaminergic neuron degeneration. Excessive reactive oxygen species formation, one of the underlying causes of pathology in the course of PD has been evidenced by various studies showing that oxidized macromolecules including lipids, proteins, and nucleic acids accumulate in brain tissues of PD patients. DNA oxidation may produce various lesions in the course of PD. Mutations incurred as a result of DNA oxidation may further enhance reactive oxygen species production in the brains of PD patients, exacerbating neuronal loss due to defects in the mitochondrial electron transport chain, antioxidant depletion, and exposure to toxic oxidized dopamine. The protein products of SNCA, PRKN, PINK1, DJ1, and LRRK2 genes are associated with disrupted oxidoreductive homeostasis in PD. SNCA is the first gene linked with familial PD and is currently known to be affected by six mutations correlated with the disorder: A53T, A30P, E46K, G51D, H50Q and A53E. PRKN encodes Parkin, an E3 ubiquitin ligase which mediates the proteasome degradation of redundant and disordered proteins such as glycosylated α-synuclein. Over 100 mutations have been found among the 12 exons of PRKN. PINK1, a mitochondrial kinase highly expressed in the brain, may undergo loss of function mutations which constitute approximately 1–8% of early onset PD cases. More than 50 PD-promoting mutations have been found in PINK1. Mutations in DJ-1, a neuroprotective protein, are a rare cause of early onset PD and constitute only 1% of cases. Around 20 mutations have been found in DJ1 among PD patients thus far. Mutations in the LRRK2 gene are the most common known cause of familial autosomal dominant PD and sporadic PD. Treatment of PD patients, especially in the advanced stages of the disease, is very difficult. The first step in managing progressive PD is to optimize dopaminergic therapy by increasing the doses of dopamine agonists and L-dopa. The next step is the introduction of advanced therapies, such as deep brain stimulation. Genetic factors may influence the response to L-dopa and deep brain stimulation therapy and the regulation of oxidative stress. Consequently, research into minimally invasive surgical interventions, as well as therapies that target the underlying etiology of PD is warranted.

Individual susceptibility has a major impact on strong association between oxidative stress, defence systems and Parkinson's disease

NFE2L2 variations reduce antioxidant response in patients with Parkinson disease.

Oxidative Stress in Parkinson's Disease: A Systematic Review and Meta-Analysis

Oxidative stress factors in Parkinson’s disease

Bidirectional two-sample Mendelian randomization analysis identifies causal associations between oxidative stress and Parkinson's disease

Elevated Serum Xanthine Oxidase and Its Correlation with Antioxidant Status in Patients with Parkinson's Disease

Oxidative Stress-Induced Signaling Pathways Implicated in the Pathogenesis of Parkinson’s Disease

Iron and Oxidative Stress in Parkinson’s Disease: An Observational Study of Injury Biomarkers

Oxidative Modification and Its Implications for the Neurodegeneration of Parkinson's Disease

Genetic Impacts on Nigral Iron Deposition in Parkinson's Disease: A Preliminary Quantitative Susceptibility Mapping Study.

Potential roles of oxidative distress on neurodegeneration in Parkinson's disease with neuropsychiatric symptoms

Parkinson'S Disease is Accompanied by Intertwined Alterations in Iron Metabolism and Activated Immune-Inflammatory and Oxidative Stress Pathways

Contra-Directional Expression of Plasma Superoxide Dismutase with Lipoprotein Cholesterol and High-Sensitivity C-reactive Protein As Important Markers of Parkinson's Disease Severity

Highly Specific Changes in Antioxidant Levels and Lipid Peroxidation in Parkinson’s Disease and Its Progression: Disease and Staging Biomarkers and New Drug Targets

Intake of Antioxidant Vitamins and Risk of Parkinson's Disease.

Mitochondria as an easy target to oxidative stress events in Parkinson's disease.

Oxidative stress: A major pathogenesis and potential therapeutic target of antioxidative agents in Parkinson's disease and Alzheimer's disease.

Oxidative stress gene polymorphisms may have an impact in the development of ischemic stroke

Food and Food Waste Antioxidants: Could They Be a Potent Defence against Parkinson's Disease?

Astrocytic Oxidative/Nitrosative Stress Contributes to Parkinson’s Disease Pathogenesis: The Dual Role of Reactive Astrocytes

Association between the risk and severity of Parkinson's disease and plasma homocysteine, vitamin B12 and folate levels: a systematic review and meta-analysis